Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Taina Rosa, Olivia Meyer
05.19.26
Pillsbury advised Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, on its recent acquisition of longstanding partner Endospan Ltd., a pioneer in the endovascular repair of aortic arch disease and developer of the NEXUS® Aortic Arch System.
The acquisition resulted from Artivion’s exercise of an option to acquire Endospan that was originally negotiated and entered into in 2019. The U.S. Food and Drug Administration approved the premarket approval application for Endospan’s NEXUS® branched endovascular stent graft system in April 2026. Artivion has acted as the exclusive distributor of the NEXUS® System across Europe, the Middle East and Africa since 2019, underscoring the longstanding commercial relationship between the parties.
The base purchase price was $175 million and was subject to adjustments for, among other things, working capital, indebtedness, cash and transaction expenses, and amounts previously loaned from Artivion to Endospan, resulting in an upfront net acquisition cost of approximately $131.3 million. The purchase agreement also provides for additional contingent payments of up to $200 million tied to future commercial performance.
Click here to read the full article.
The Pillsbury deal team was led by Corporate partner Andy Smetana, who has been involved in this matter since 2019. The team also included Corporate special counsel Danielle de Zorzi and associate Lee Alexander; Executive Compensation & Benefits partner Jessica Lutrin; and Tax partner Joshua Becker. Artivion’s Israeli counsel for this transaction was Barnea Jaffa Lande & Co.